A GLP-1 receptor agonist
GLP-1 receptor agonists, combined with nanoparticle delivery and synergistic agents, provide an effective treatment for NAFLD and NASH by reducing hepatic fat, improving liver function, and preventing fibrosis with minimal side effects.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- MAHRAT REEM
- Filing Date
- 2025-10-10
- Publication Date
- 2026-06-18
AI Technical Summary
Current treatment options for non-alcoholic fatty liver disease (NAFLD) and its advanced form, non-alcoholic steatohepatitis (NASH), are limited, and there is an urgent need for effective therapeutic interventions that can reduce hepatic fat content, improve liver function, and prevent fibrosis while minimizing side effects.
The use of GLP-1 receptor agonists, such as liraglutide, semaglutide, exenatide, dulaglutide, or modified GLP-1 analogs, in combination with nanoparticle delivery systems for targeted liver delivery, along with synergistic agents like SGLT-2 inhibitors, PPAR agonists, FXR agonists, and statins, to enhance efficacy and reduce side effects.
The GLP-1 receptor agonists effectively reduce hepatic fat content, improve insulin sensitivity, decrease liver inflammation, and prevent fibrosis, with reduced systemic side effects through tissue-specific delivery mechanisms.
Smart Images
Figure IMGF000015_0001 
Figure IMGF000015_0002 
Figure IMGF000015_0003